Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of ...

Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim ...

Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key therapeutic advances, standout presentations, emerging trends in oncology treatment, ...

Imdelltra Outperforms Chemotherapy in SCLC. In the Phase III DeLLphi-304 trial, Imdelltra (tarlatamab) significantly improved overall survival (13.6 months vs. 8.3 months) and progression-free ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Meanwhile, Amgen’s bispecific T-cell engager Imdelltra (tarlatamab) delivered a significant clinical benefit in the DELLphi-304 trial for patients with extensive-stage small cell lung cancer (ES-SCLC) ...

Rachna Khosla, Senior Vice President of Business Development at Amgen Inc . (NASDAQ: AMGN), a prominent biotechnology company with a market capitalization of $156.45 billion and a robust "Good" ...